Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 153Lung Neoplasms 69Carcinoma, Hepatocellular 63Small Cell Lung Carcinoma 48Breast Neoplasms 47Squamous Cell Carcinoma of Head and Neck 35Urinary Bladder Neoplasms 30Colorectal Neoplasms 30Biliary Tract Neoplasms 29Neoplasms 28Neoplasm Metastasis 28Cholangiocarcinoma 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Ovarian Neoplasms 24Liver Neoplasms 18Head and Neck Neoplasms 18Carcinoma, Renal Cell 17Recurrence 16Melanoma 14Stomach Neoplasms 13Prostatic Neoplasms 13Carcinoma 13Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Esophageal Neoplasms 11Carcinoma, Transitional Cell 11Lymphoma, Large B-Cell, Diffuse 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9

Interventions

Nivolumab 3Ipilimumab 3poly ICLC 2Specimen Handling 2Sorafenib 2Irinotecan 2Cyclophosphamide 2spartalizumab 1sapanisertib 1pembrolizumab 1fludarabine 1durvalumab 1dostarlimab 1dehydroftorafur 1balstilimab 1atezolizumab 1aflibercept 1Whole-Body Irradiation 1Watchful Waiting 1Vincristine 1Tacrolimus 1Sunitinib 1Prednisone 1Platinum 1Oxaliplatin 1Observation 1Mycophenolic Acid 1Mesna 1Leuprolide 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fibrolamellar hepatocellular carcinoma × durvalumab × Clear all
NCT06027086 2026-02-12

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡